Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for bsx
22.00
+0.08 (0.36%)
May 3 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 21.84 - 22.22
52 week 14.18 - 22.42
Open 21.92
Vol / Avg. 500.00/10.44M
Mkt cap 29.92B
P/E     -
Div/yield     -
EPS -0.18
Shares 1.35B
Beta 1.01
Inst. own 93%
Jul 21, 2016
Q2 2016 Boston Scientific Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2016
Boston Scientific Corp at Bank of America Merrill Lynch Health Care Conference - 11:00AM EDT - Add to calendar
May 5, 2016
Boston Scientific Corp Investor Update - 5:00PM EDT - Add to calendar
May 5, 2016
Boston Scientific Corp at Deutsche Bank Health Care Conference - 9:20AM EDT - Add to calendar
May 4, 2016
Boston Scientific Corp Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 3, 2016
Boston Scientific Corp Annual Shareholders Meeting
Apr 27, 2016
Q1 2016 Boston Scientific Corp Earnings Release
Apr 27, 2016
Q1 2016 Boston Scientific Corp Earnings Call - Webcast
Apr 12, 2016
Boston Scientific Corp at Needham Healthcare Conference
Apr 4, 2016
Boston Scientific Corp Investor Update on Boston Scientific Cardiovascular Portfolio
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -7.18% -3.20%
Operating margin -13.70% -4.37%
EBITD margin - 24.29%
Return on average assets -3.13% -1.36%
Return on average equity -8.95% -3.74%
Employees 25,000 -
CDP Score - 58 E

Address

300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

Officers and directors

Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President and President - Rhythm Management
Age: 52
Bio & Compensation  - Reuters
Daniel J. Brennan Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 66
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President and President - Asia-Pacific, Middle East and Africa
Age: 63
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Edward F. Mackey Executive Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President and President - MedSurg
Age: 56
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Kevin J. Ballinger Senior Vice President and President - Interventional Cardiology
Age: 43
Bio & Compensation  - Reuters